Key releases

Key releases are ad hoc announcements pursuant to SIX Swiss Exchange Art. 53 LR

November 2, 2026
Galderma Announces Proposed Board Appointments and Chief Financial Officer Transition
October 22, 2026
Galderma Delivers Net Sales of 4.765 B USD in the First Nine Months, Up 25.1% at Constant Currency Year-on-Year, and Raises Full-Year Net Sales Guidance
October 14, 2026
Galderma Signs Agreement to Acquire ZO Skin Health, Strengthening Its Physician-Dispensed Skincare Offering
July 23, 2026
Galderma Reports Record First Half 2026 Net Sales of 3.134 Billion USD and 24.6% Year-on-Year Growth at Constant Currency, Raises Net Sales Guidance for the Full Year
July 1, 2026
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States
April 23, 2026
Galderma Reports Strong Start to the Year, Delivering First Quarter 2026 Net Sales of 1.473 Billion USD, Growing 25.5% at Constant Currency
March 11, 2026
Galderma Buys Back Shares Worth CHF 232 Million in the Context of Accelerated Bookbuild Offering
March 5, 2026
Galderma Delivers Record 2025 Results With Net Sales of 5.207 Billion USD, up 17.7% at Constant Currency¹, and Core EBITDA² of 1.211 billion USD, Growing 18.9% at Constant Currency
February 16, 2026
Galderma Announces Appointment of New Chief Financial Officer
December 8, 2025
Galderma Welcomes Increased Equity Investment From L’Oréal
Displaying 1 - 10 of 27